Allotransplants in persons with leukaemia are associated with a decreased leukaemia relapse risk compared with transplants from genetically-identical twins. There is considerable controversy whether this operational anti-leukaemia effect, sometimes termed graft-versus-leukaemia (GvL), is immunologically specific to the leukaemia or results from donor immune cells reacting to disparate recipient HLA and non-HLA histocompatibility antigens on leukaemia cells or both. If so, this effect is better seen as an aspect of GvHD. These theoretical distinctions are presented schematically in Figure 1 .
We previously studied leukaemia relapse rates in 2264 persons with acute and chronic leukaemias receiving T-cell replete or -depleted transplants from diverse donors including HLA-matched siblings and who were diagnosed or not as having acute and/or chronic GvHD. 1 We included a comparator cohort of recipients of T-cell replete transplants from genetically-identical twins. Our analyses, reproduced in Figure 2 , identified the highest leukaemia relapse rate in recipients of T-cell replete transplants from genetically-identical twins and the lowest in recipients of T-cell replete allotransplants diagnosed with acute and chronic GvHD. Recipients of T-cell-depleted allotransplants not diagnosed with acute or chronic GvHD had a significantly higher risk of leukaemia relapse than similar recipients of T-cell replete allotransplants also not diagnosed with acute or chronic GvHD. On the basis of these data we postulated two anti-leukaemia effects in the setting of allotransplants: (1) an anti-leukaemia effect associated with a diagnosis of acute or chronic GvHD (or both), but especially chronic GvHD and (2) a separate anti-leukaemia effect in persons not diagnosed with acute or chronic GvHD likely mediated by T cells (or by cells removed by diverse techniques and labelled as T-cell depletion in our study). We could not, of course, distinguish between an allogeneic leukaemia-specific immune response and a non-leukaemia-specific alloimmune effect in persons with no diagnosis of acute or chronic GvHD. The latter possibility is of considerable concern given the difficulty in accurate diagnosis of acute GvHD (for example, Pidala et al.
2 ). However, there is less discordance in the diagnosis of chronic GvHD that was associated with the lowest risk of leukaemia relapse. 3 These data did not allow us to determine whether there might be an allogeneic nonspecific anti-leukaemia effect distinct from chronic GvHD. For example, an immune reaction to disparate HLA-or non-HLA histocompatibility antigens might release cytokines such as interferons or interleukins to which leukaemia cells might be more sensitive than normal cells. Such an effect would be operationally, but not immunologically, leukaemia-specific. However, a person with leukaemia and his/her physician might not care if the effect was operationally or immunologically specific provided the risk of leukaemia relapse was less.
There is recent considerable interest and data in persons with leukaemia receiving allotransplants from HLA-haplotype-matchedrelated donors. These data were not included in our prior analyses (reviewed in Bacigalupo and Sica 4 and Kanakry et al.
5
). One approach to preventing acute and chronic GvHD in this setting is to give high doses of cyclophosphamide immediately post transplant. This intervention markedly reduces the risk of being diagnosed with chronic GvHD; the impact on reducing acute GvHD is less dramatic. Because chronic GvHD was associated with the lowest leukaemia relapse risk in our prior analyses, we wondered whether using post-transplant cyclophosphamide in this setting was associated with an increased risk of leukaemia relapse. The answer seems no. For example, persons with AML receiving an HLA-haplotype-matched transplant and posttransplant cyclophosphamide have a significantly lower incidence of chronic GvHD than recipients of HLA-matched unrelated transplants, but no increase in leukaemia relapse risk. 6 Similarly, a lower incidence of chronic GvHD with no increase in leukaemia relapse risk was reported in a cohort of subjects receiving a HLA-haplotype-matched transplant with post-transplant cyclophosphamide compared with recipients of HLA-identical sibling transplants for lymphoma. 7 One possible explanation why decreasing the proportion of persons diagnosed with chronic GvHD did not result in more leukaemia relapses is the direct antileukaemia activity of cyclophosphamide given post transplant. This seems unlikely as the amount of cyclophosphamide given pre-and post transplant did not differ between persons with AML receiving HLA-haplotype-matched transplants compared with those receiving HLA-matched unrelated transplant after conventional conditioning regimens of cyclophosphamide and total-body radiation or busulfan.
Although these data do not exclude the possibility of an alloimmune effect that decreases leukaemia relapse risk but is distinct from chronic GvHD, it is most consistent with an immune-mediated specific anti-leukaemia effect distinct from chronic GvHD reasonably termed GvL. Whether these persons might have undiagnosed chronic GvHD or some other alloimmune response to disparate HLA and non-HLA histocompatibility antigens is unknown and probably unknowable. Regardless of the mechanism of action, cells mediating this effect seem relatively resistant to high-dose cyclophosphamide. This contrasts with susceptibility of the cells mediating chronic GvHD. Another possibility is recipient-derived immune cells with specific antileukaemia activity survive pretransplant conditioning and are activated in an allogeneic milieu to eradicate leukaemia cells without causing diagnosable GvHD, perhaps until these cells are eliminated by the non-specific graft-versus-host reaction (as distinct from diagnosed GvHD). For example, host T cells were reported to effect anticancer immunity after non-myeloablative allotransplants, donor lymphocyte infusion and vaccination in a mouse model of breast cancer. 8 Others report specific anti-leukaemia effects of T-cells recognising neoantigens on CLL cells. 9 A third possibility is that donor natural-killer cells in the HLA-haplotype-matched graft or developing post transplant have an anti-leukaemia effect unassociated with GvHD. And there are other more convoluted explanations.
One indirect way to determine if there is a specific immune-mediated anti-leukaemia effect is to consider whether incidence of leukaemia is increased in persons without or with a defective immune system. Examples include children with congenital or inherited immune deficiency disorders, adults with acquired immune deficiency (common variable immune deficiency and AIDS) and recipients of solid organ transplants receiving lifelong immune suppression. There are few convincing data of a substantial increased leukaemia risk in these persons except for virus-associated leukaemias and lymphomas (reviewed in Vajdic and van Leeuwen 10 ). We analysed 248 224 recipients of kidney, heart, lung and heart-lung grafts and found only a slight increase in AML in recipients of heart transplants. 11 These persons receive intense immune suppression but are also exposed to high doses of ionising radiations for diagnostic studies. Because such exposures are independently-associated with an increased risk of AML it is not possible to quantify what role, if any, their increased risk of AML is related to immune suppression. 12 Several other studies support the notion of an anti-leukaemia effect independent of the diagnosis of acute and/or chronic GvHD (again highly confounded). Two small phase-2 non-randomized studies reported grafts of CD34-positive cells decrease the likelihood of being diagnosed with chronic and possibly acute GvHD without increasing leukaemia relapse compared with historic controls. 13, 14 Because most or all immune cells were removed from the graft post transplant, anti-leukaemia activity was either mediated by other mechanisms (such as cytokines) or by immune cells developing from the graft (or both). A retrospective, non-pre-specified analysis of a phase-2 study of umbilical cord blood cell transplants reported a lower leukaemia relapse risk without more diagnosed acute or chronic GvHD. 15 A similar result was reported in a small phase-3 study. 16 And as we mentioned above, leukaemia-specific T cells are sometimes found in people with CLL.
Our bottom line? The data we cite indicate a potent anti-leukaemia effect of allotransplants, especially HLAhaplotype-matched transplants with high-dose post-transplant cyclophosphamide, in persons not diagnosed with chronic GvHD.
Hopefully new studies will identify how this anti-leukaemia effect is mediated and whether it is leukaemia-specific or a forme fruste of GvHD. We would be pleased with either mechanism and especially with both. Figure 1 . GvHD and GvL. The large circle represents allotransplant recipients with acute and/or chronic GvHD. The red circle within it represents those diagnosed with acute and/or chronic GvHD (true positives) and the pink rim those with acute and/or chronic GvHD who were undiagnosed (false negatives). The green circle (partially hidden behind the red) represents persons in whom there is less leukaemia relapse (a GvL effect). The green crescent not overlapping the GvHD circle represents an immune-specific anti-leukaemia effect distinct from acute and/or chronic GvHD. 
